Cost-Effectiveness and Budget Impact Analysis of Apatinib for Advanced Metastatic Gastric Cancer from the Perspective of Health Insurance System
Objective. This study evaluated the cost-effectiveness of apatinib in patients with chemotherapy-refractory mGC. Patients and Methods. A Markov model was developed to simulate the clinical course of typical patients with chemotherapy-refractory metastatic gastric cancer (mGC). We estimated the 10-ye...
Saved in:
| Main Authors: | Yongrui Bai, Yuejuan Xu, Bin Wu |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2017-01-01
|
| Series: | Gastroenterology Research and Practice |
| Online Access: | http://dx.doi.org/10.1155/2017/2816737 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Safety and efficacy of apatinib in combination treatment versus apatinib as second-line treatment for advanced gastric cancer
by: Zhang Han, et al.
Published: (2025-04-01) -
Efficacy and safety of apatinib in the second-line treatment of advanced gastric cancer
by: GUO Mengya, CHEN Yue, PENG Weiwei, SHA Huanhuan, FANG Ying, ZHOU Guoren
Published: (2025-01-01) -
Cholesterol confers resistance to Apatinib-mediated ferroptosis in gastric cancer
by: Zhiwei Li, et al.
Published: (2025-07-01) -
Analysis of the correlation between the dose exposure intensity and apatinib in advanced gastric cancer: a retrospective cohort study
by: Xiao Ma, et al.
Published: (2025-02-01) -
Camrelizumab combined with apatinib plus irinotecan as a second-line treatment in advanced or metastatic esophageal squamous cell carcinoma patients
by: Shusheng Wu, et al.
Published: (2025-05-01)